Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Chronic cholestasis often results in premature death from liver failure with fibrosis; however, the molecular mechanisms contributing to biliary cirrhosis are not demonstrated. In this article, we show that the death signal mediated by TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/death receptor 5 (DR5) may be a key regulator of cholestatic liver injury. Agonistic anti-DR5 monoclonal antibody treatment triggered cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury in a mouse strain-specific manner. TRAIL- or DR5-deficient mice were relatively resistant to common bile duct ligation-induced cholestasis, and common bile duct ligation augmented DR5 expression on cholangiocytes, sensitizing mice to DR5-mediated cholangitis. Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance, reminiscent of human primary sclerosing cholangitis. Human cholangiocytes constitutively expressed DR5, and TRAIL expression and apoptosis were significantly elevated in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients. Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360 · cited 4×
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundInfluentialBid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004 · cited 1×
“The mitochondrial pathway of apoptosis appeared to play a limited role in anti-DR5 mAb-induced cholestatic liver injury, because disease onset was only partly delayed in B6 Bid / mice that are resistant to Fas-induced hepatocellular apoptosis (26) [supporting information (SI) Fig.”
BackgroundJo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775 · cited 2×
“TRAIL has been also demonstrated as a critical molecule in extrinsic tumor suppression by the immune system (3, 7, 8), and thus TRAIL is of great interest to clinical oncologists (3, 9).”
BackgroundResultSelf-citationDifferential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Essential roles of the Fas ligand in the development of hepatitis
Kondo, T., Suda, T., Fukuyama, H., Adachi, M., & Nagata, S. (1997) · Nature Medicine · doi:10.1038/nm0497-409 · Cited by 479 · cited 1×
“Furthermore, TNF/TNF-receptor superfamilies contribute to a number of diseases, and TNF- and Fas ligandinduced hepatocyte death have particularly been shown to play a critical role in hepatic disorders (17).”
BackgroundKayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1451 · Cited by 479
Self-citationTakeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465 · cited 1×
“TRAIL has been also demonstrated as a critical molecule in extrinsic tumor suppression by the immune system (3, 7, 8), and thus TRAIL is of great interest to clinical oncologists (3, 9).”
BackgroundSelf-citationEksteen, B., Grant, A. J., Miles, A., Curbishley, S. M., Lalor, P. F., Hübscher, S. G., Briskin, M., Salmon, M., & Adams, D. H. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041035 · Cited by 360 · cited 1×
“Possible mechanisms may include the following: activated gut T cells emigrating to the liver (35) or immune responses against normal flora or their metabolites (23) may play a pathogenic role to produce type I IFNs or IFN- (36) that induce TRAIL expression and augment the TRAIL sensitivity (8, 37–39); or autoantibodie…”
BackgroundTolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314 · cited 1×
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundIFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
Fulda, S., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205255 · Cited by 260
Primary sclerosing cholangitis: Summary of a workshop
LaRusso, N. F., Shneider, B. L., Black, D., Gores, G. J., James, S. P., Doo, E., & Hoofnagle, J. H. (2006) · Hepatology · doi:10.1002/hep.21337 · Cited by 251 · cited 1×
“The pathogenesis of PSC is largely unknown, although immune response has been proposed to play a role (23, 24, 34).”
BackgroundPhase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247 · cited 2×
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundDirect Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
Ricci, M. S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D. T., & El-Deiry, W. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8541-8555.2004 · Cited by 243 · cited 1×
“S1C), both alterations may sensitize these strains to TRAIL/DR5-mediated apoptosis (28).”
BackgroundHamilton, S. E., Wolkers, M. C., Schoenberger, S. P., & Jameson, S. C. (2006) · Nature Immunology · doi:10.1038/ni1326 · Cited by 216 · cited 1×
“TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L binds two death receptors [TRAIL-R1/death receptor 4 (DR4) and TRAIL-R2/death receptor 5 (DR5)] (3), and has been recently identified as a key molecule in immune regulation of T cells [memory CD8 T cell control by CD4 T cells (4, 5) and Th2 cell response (6)].”
BackgroundInduction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
Takeda, K., Yamaguchi, N., Akiba, H., Kojima, Y., Hayakawa, Y., Tanner, J. E., Sayers, T. J., Seki, N., Okumura, K., Yagita, H., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031457 · Cited by 206 · cited 8×
“FasL- and TRAIL-sensitive L929, mouse TRAIL-transfected 2PK-3, mouse Fas ligand (FasL)-transfected L5178Y, and Fc receptor-expressing P815 cells have been prepared as described previously (14).”
BackgroundMethodInfluentialSelf-citationIsotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Interferons as pathogenic effectors in autoimmunity
Baccala, R., Kono, D. H., & Theofilopoulos, A. N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00252.x · Cited by 199
Targeting death-inducing receptors in cancer therapy
Takeda, K., Stagg, J., Yagita, H., Okumura, K., & Smyth, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210374 · Cited by 186 · cited 2×
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundSelf-citationCritical roles of TRAIL in hepatic cell death and hepatic inflammation
Zheng, S.-J., Wang, P., Tsabary, G., & Chen, Y. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19255 · Cited by 173
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
Ishimura, N., Isomoto, H., Bronk, S. F., & Gores, G. J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00242.2005 · Cited by 156 · cited 1×
“TRAIL has been reported to promote the migration and invasion of cholangiocarcinoma cells (41), and this might be the reason for a higher risk of developing cholangiocarcinoma in PSC patients (23, 24).”
BackgroundCritical roles of TRAIL in hepatic cell death and hepatic inflammation
Zheng, S. J., Wang, P., Tsabary, G., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419255 · Cited by 150
TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice
Hao, C., Song, J. H., Hsi, B., Lewis, J., Song, D. K., Petruk, K. C., Tyrrell, D. L. J., & Kneteman, N. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2599 · Cited by 148
Volkmann, X., Fischer, U., Bahr, M. J., Ott, M., Lehner, F., MacFarlane, M., Cohen, G. M., Manns, M. P., Schulze-Osthoff, K., & Bantel, H. (2007) · Hepatology · doi:10.1002/hep.21846 · Cited by 141 · cited 1×
“Some preparations of recombinant TRAIL or agonistic mAbs specific for DR4 or DR5 were reported as cytotoxic against cultured hepatocytes (18–20) and diseased human liver (21).”
BackgroundThe Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion
Aggarwal, B. B., Shishodia, S., Ashikawa, K., & Bharti, A. C. (2002) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010023344571 · Cited by 131 · cited 1×
“T and TNF-receptor superfamilies play indispensable roles in immunity and inflammatory responses (1, 2).”
BackgroundXu, B., Broome, U., Ericzon, B.-G., & Sumitran-Holgersson, S. (2002) · Gut · doi:10.1136/gut.51.1.120 · Cited by 124
Weckmann, M., Collison, A., Simpson, J. L., Kopp, M., Wark, P. A. B., Smyth, M. J., Yagita∥, H., Matthaei, K. I., Hansbro, N. G., Whitehead, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1660 · Cited by 123 · cited 1×
“TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L binds two death receptors [TRAIL-R1/death receptor 4 (DR4) and TRAIL-R2/death receptor 5 (DR5)] (3), and has been recently identified as a key molecule in immune regulation of T cells [memory CD8 T cell control by CD4 T cells (4, 5) and Th2 cell response (6)].”
BackgroundSelf-citationHuman normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2
Mori, E., Thomas, M., Motoki, K., Nakazawa, K., Tahara, T., Tomizuka, K., Ishida, I., & Kataoka, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401331 · Cited by 93
TRAIL mediates liver injury by the innate immune system in the bile duct–ligated mouse†
Kahraman, A., Barreyro, F. J., Bronk, S. F., Werneburg, N. W., Mott, J. L., Akazawa, Y., Masuoka, H. C., Howe, C. L., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22136 · Cited by 90
Higuchi, H., Bronk, S. F., Taniai, M., Canbay, A. E., & Gores, G. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040030 · Cited by 89 · cited 2×
“CBD ligation was performed in 6- to 8-week-old mice as previously described (32).”
BackgroundMethodGores, G., & Kaufmann, S. H. (2001) · Hepatology · doi:10.1053/jhep.2001.25173 · Cited by 88
Harada, K., Sato, Y., Itatsu, K., Isse, K., Ikeda, H., Yasoshima, M., Zen, Y., Matsui, A., & Nakanuma, Y. (2007) · Hepatology · doi:10.1002/hep.21797 · Cited by 88
Self-citationWerner, A. B., de Vries, E., Tait, S. W. G., Bontjer, I., & Borst, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204351200 · Cited by 64 · cited 5×
“Yin XM, et al. (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis.”
BackgroundInfluentialManagement of primary sclerosing cholangitis
Lee, Y. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)04147-8 · Cited by 63
Katayanagi, K., Kono, N., & Nakanuma, Y. (1998) · Liver · doi:10.1111/j.1600-0676.1998.tb00133.x · Cited by 54
Self-citationRole of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes
Musallam, L., Éthier, C., Haddad, P. S., & Bilodeau, M. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.280.6.g1360 · Cited by 50 · cited 1×
“Mice hepatocytes, biliary epithelial cells, or intrahepatic biliary tree was isolated as previously reported (25, 42, 43).”
MethodCurrent management of primary biliary cirrhosis and primary sclerosing cholangitis
Levy, C., & Lindor, K. D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00006-0 · Cited by 33 · cited 7×
“The pathogenesis of PSC is largely unknown, although immune response has been proposed to play a role (23, 24, 34).”
BackgroundInfluentialIsolation of functional polarized bile duct units from mouse liver
Cho, W. K., Mennone, A., & Boyer, J. L. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.280.2.g241 · Cited by 28 · cited 2×
“Mice hepatocytes, biliary epithelial cells, or intrahepatic biliary tree was isolated as previously reported (25, 42, 43).”
BackgroundMethodGardnerova, M., Blanqué, R., & Gardner, C. (2000) · Current Drug Targets · doi:10.2174/1389450003349092 · Cited by 21
Research works printed but not linked: 2
- 10.1111/j.1572-0241.2002.05585.x · doi:10.1111/j.1572-0241.2002.05585.x · Paper page
- 10.1053/jhep.2001.25173a · doi:10.1053/jhep.2001.25173a
Cited by
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
“, and two recent studies have shown that the TRAIL-DR5 pathway may contribute to hepatotoxicity and bile duct toxicity in mice either treated with anti-mouse DR5 mAb or intervened by bile duct ligatio”
BackgroundSelf-citationCell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Hepatocyte Death: A Clear and Present Danger
Malhi, H., Guicciardi, M. E., & Gores, G. J. (2010) · Physiological Reviews · doi:10.1152/physrev.00061.2009 · Cited by 477
“In particular, DR5 expression is increased in the liver of bile duct-ligated mice and in liver cells exposed to toxic bile acids (106, 108, 250).”
InfluentialPathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
“Mice injected with death receptor 5 agonists have also provided insight into apoptosis in cholestatic liver disease.(98) Given the heterogeneity of PSC and the many factors that contribute to its pathogenesis, a single animal model will be challenging to develop.”
BackgroundApoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Metadata
- Authors
- Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., Cretney, E., Yagita, H., Sueyoshi, N., Sato, N., Nakanuma, Y., Smyth, M. J., & Okumura, K.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Trung tâm Nghiên cứu Y sinh (VN)
- Juntendo University (JP)
- Kanazawa University (JP)
- University of Bern (CH)
- *Department of Immunology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-05
- Volume
- 105
- Issue
- 31
- Pages
- 10895-10900
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2504811
- OpenAlex
- W2171653534
- Semantic Scholar
- 808def9695bd321dc3e05100e71a911d21259847
- Cited by
- 148
- References
- 45
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 12 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 11 · 2018: 3 · 2017: 13 · 2016: 2 · 2015: 6 · 2014: 10 · 2013: 14 · 2012: 11
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- DR5, TRAIL receptor 2, apoptosis, cholestatic liver disease, primary sclerosing cholangitis, primary biliary cirrhosis, cholangiocytes, cholangitis, common bile duct ligation, liver fibrosis, TRAIL
- MeSH terms
- Animals, Antibodies, Monoclonal, Cholangitis, Cholestasis, Flow Cytometry, Humans, Immunohistochemistry, Mice, Mutant Strains, Apoptosis, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.